Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients
Altundag, K.
Journal of Buon Official Journal of the Balkan Union of Oncology 23(5): 1559-1560
2018
ISSN/ISBN: 1107-0625 PMID: 30570888 Document Number: 695947
Document emailed within 1 workday
Related Documents
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Spigel, D.R.; Hainsworth, J.D.; Burris, H.A.; Molthrop, D.C.; Peacock, N.; Kommor, M.; Vazquez, E.R.; Greco, F.A.; Yardley, D.A. 2011: A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer Clinical Advances in Hematology and Oncology: H&o 9(4): 280-286
Wen, H.-w.; Tian, F.; Ma, L.; Liao, Q.-p. 2009: Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer Zhonghua Fu Chan Ke Za Zhi 44(3): 196-199
Sutepvarnon, A.; Warnnissorn, M.; Srimuninnimit, V. 2013: Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer Journal of the Medical Association of Thailand 96(Suppl 2): S60-S66
Kubota, O.; Onuki, Y.; Uchiyama, T.; Oishi, K.; Takeda, M. 2012: Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(5): 753-757
Altundag, K. 2017: Predictive markers for trastuzumab-associated cardiac dysfunction in patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab Journal of BUON: Official Journal of the Balkan Union of Oncology 22(3): 801
Taguchi, K.; Iihara, H.; Ishihara, M.; Komori, Y.; Tanizawa, K.; Matsuura, K.; Itoh, Y. 2009: Comparison of antiemetic efficacy between single and repeated treatments with a 5-HT3 receptor antagonist in breast cancer patients with high-risk emetogenic chemotherapy Anticancer Research 29(5): 1721-1725
Partridge, A.H.; Niman, S.M.; Ruggeri, M.; Peccatori, F.A.; Azim, H.A.; Colleoni, M.; Saura, C.; Shimizu, C.; Sætersdal, A.B.; Kroep, J.R.; Mailliez, A.; Warner, E.; Borges, V.F.; Amant, F.éd.ér.; Gombos, A.; Kataoka, A.; Rousset-Jablonski, C.; Borstnar, S.; Takei, J.; Lee, J.E.; Walshe, J.M.; Borrego, M.R.íz.; Moore, H.C.; Saunders, C.; Cardoso, F.; Susnjar, S.; Bjelic-Radisic, V.; Smith, K.L.; Piccart, M.; Korde, L.A.; Goldhirsch, A.; Gelber, R.D.; Pagani, O. 2021: Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy Breast 59: 327-338
Brandt, M.E.; Puett, D.; Garola, R.; Fendl, K.; Covey, D.F.; Zimniski, S.J. 1988: Aromatase and aromatase inhibitors: from enzymology to selective chemotherapy Progress in Clinical and Biological Research 262: 65-84
Perez, E.; Muss, H.B. 2005: Optimizing adjuvant chemotherapy in early-stage breast cancer Oncology 19(14): 1759-1767; Discussion 1768: 1772-1774; 1777-1778
Karatas, F.; Akin, S.; Babacan, T.; Sever, A.R.; Altundag, K. 2015: Can aromatase inhibitors cause forgetfulness in women with breast cancer ? Journal of BUON: Official Journal of the Balkan Union of Oncology 20(3): 935
Rugo, H.S. 2019: Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer Clinical Advances in Hematology and Oncology: H&o 17(10): 555-558
Bershteĭn, L.M.; Barchuk, A.S.; Gershfel'd, E.D.; Kovalevskiĭ, A.I.; Maksimov, S.I.; Danilova, M.A.; Barash, I.A.; Meshkova, I.E.; Moiseenko, V.M.; Novik, A.V.; Pozharisskiĭ, K.M.; Semiglazov, V.F.; Tsyrlina, E.V.; Chernobrovkina, A.E. 2007: Use of aromatase and its inhibitors in dealing with different oncological pathologies other than breast cancer Voprosy Onkologii 53(1): 7-13
Harvey, H.A. 1998: Emerging role of aromatase inhibitors in the treatment of breast cancer Oncology 12(3 Suppl 5: 32-35
Tsukamoto, T.; Fukui, I.; Kihara, K.; Goto, S.; Kitahara, S.; Kobayashi, T.; Kojima, S.; Oshima, H. 1996: Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy Hinyokika Kiyo. Acta Urologica Japonica 42(5): 351-356
Wang, S.-l.; Li, Y.-x.; Song, Y.-w.; Wang, W.-h.; Jin, J.; Liu, Y.-p.; Liu, X.-f.; Yu, Z.-h. 2010: Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy Zhonghua Zhong Liu Za Zhi 32(7): 520-525
Fox, R.M.; Adiseshan, N. 1977: Adjuvant chemotherapy, early breast cancer and positive bone scan Medical Journal of Australia 1(10): 347-348
Fukuoka, M.; Kitawaki, J.; Yamamoto, T.; Okada, H. 1991: Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors Nihon Sanka Fujinka Gakkai Zasshi 43(12): 1667-1673
Fujinaka, R.; Otowa, Y.; Yokoo, H.; Arai, K.; Murata, K.; Mii, Y.; Kakinoki, K.; Oka, S.; Kuroda, D. 2019: Adjuvant Chemotherapy for High-Risk Stage Ⅱ Colon Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(8): 1327-1329